Appointments and Affiliations
Ph.D., University of California, Biostatistics, 2004.
B.S, University of Texas, Statistics, 1997.
- Design and analysis of clinical trials for vaccines against infectious diseases
- Statistical methods in immunological assay validation and evaluation
- Statistical methods in equivalence testing
- Immune correlates of protection
2010-2011: Director, Data Analysis Unit, Statistical Center for HIV/AIDS Research and Prevention
2004-2009: Staff Scientist, Statistical Center for HIV/AIDS Research and Prevention.
2004: Bioinformatics Specialist, The Salk Institute, Plant Biology Laboratory.
2001-2003: Statistical Consultant, University of California, Los Angeles, Array Data Analysis Group, Department of Biostatistics.
2002: Research Assistant, University of California, Los Angeles, Department of Human Genetics and Department of Biostatistics.
2000-2002: Research Assistant, University of California, Los Angeles, Department of Biostatistics.
1999: Research Assistant, University of Texas at Austin, Department of Civil Engineering.
Collaboration of AIDS Vaccine Discovery (CAVD), Head, Biostatistics Collaboration, Appointed: 2011
Statistical Center for HIV/AIDS Research and Prevention, HVTN SDMC Leadership Team
Member, Appointed: 2011
Member, Appointed: 2011
2009: Invited member, FHCRC/UW delegation to China CDC, Delegation Chairs: Dr. Lee Hartwell
2008: Invited member, FHCRC/UW delegation to China CDC, Beijing, Delegation Chairs: Drs. Tuofu Zhu & Steve Self
2004-present: International Society for Computational Biology
2003-present: American Statistical Association
Honors and Awards
2002-2003: Dissertation Fellowship, Graduate Division at UCLA
2002-2003: Phi Beta Kappa Fellowship (PBK)
2002: Raymond D. Goodman Scholarship, School of Public Health at UCLA
2000: Young Investigator Award, Transplant 2000
2000: School of Public Health Travel Grant, UCLA
1999: George R. Jordan, Actuarial Science Scholarship, UT Austin
2010-present: Editorial Board Member, Journal of AIDS & Clinical Research
- Bill & Melinda Gates Foundation, Vaccine Immunology Statistical Center (VISC), Head of Biostatistical Unit, (PI: Steven Self), 2011-2016.
- NIH/NIAID: Leadership for HIV/AIDS Clincal Trials Networks: HIV Vaccine Trials Network, (PI: Steven Self), 2006-2013.
Power/sample size calculations for assessing correlates of risk in clinical efficacy trials.. Statistics in medicine.. 2016.
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.. Current opinion in virology. 17:57-65.. 2016.
Use of placebos in Phase 1 preventive HIV vaccine clinical trials.. Vaccine. 33(6):749-52.. 2015.
New clinical trial designs for HIV vaccine evaluation.. Current opinion in HIV and AIDS. 8(5):436-41.. 2013.
Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.. 2013.
Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study).. The Journal of infectious diseases. 206(2):258-266.. 2012.
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. The Journal of clinical investigation. 122(1):359-67.. 2012.
Comparability and reproducibility of biomedical data.. Briefings in bioinformatics.. 2012.
Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error.. Statistics in medicine. 31(28):3748-59.. 2012.
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86.. 2012.
Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.. Journal of immunological methods. 375(1-2):57-67.. 2012.
HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable.. Journal of immunology (Baltimore, Md. : 1950). 187(6):3391-3401.. 2011.
Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1.. Journal of acquired immune deficiency syndromes (1999). 58(3):248-52.. 2011.
Timing of Plasmid Cytokine (IL-2/Ig) Administration Affects HIV-1 Vaccine Immunogenicity in HIV-Seronegative Subjects.. The Journal of infectious diseases. 204(10):1541-1549.. 2011.
Impact of Herpes Simplex Virus Type 2 on HIV-1 Acquisition and Progression in an HIV Vaccine Trial (the Step Study).. Journal of acquired immune deficiency syndromes (1999). 57(3):238-244.. 2011.
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.. The Journal of infectious diseases. 203(8):1165-73.. 2011.
Equivalence of ELISpot assays demonstrated between major HIV network laboratories.. PloS one. 5(12):e14330.. 2010.
In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.. PloS one. 5(2):e9310.. 2010.
A Comparison of Testing Parameters and the Implementation of a Group Sequential Design for Equivalence Studies Using Paired-Sample Analysis. Statistics in Biopharmaceutical Research. 2(3):336-347.. 2010.